Cargando…

Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer’s disease

The symptomatic drugs currently on the market for Alzheimer’s disease (AD) have no effect on disease progression, and this creates a large unmet medical need. The type of drug that has developed most rapidly in the last decade is immunotherapy: vaccines and, especially, passive vaccination with mono...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lannfelt, Lars, Möller, Christer, Basun, Hans, Osswald, Gunilla, Sehlin, Dag, Satlin, Andrew, Logovinsky, Veronika, Gellerfors, Pär
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4054967/ https://www.ncbi.nlm.nih.gov/pubmed/25031633 http://dx.doi.org/10.1186/alzrt246

Ejemplares similares

Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody
por: Logovinsky, Veronika, et al.
Publicado: (2016)

Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer's disease
por: Satlin, Andrew, et al.
Publicado: (2016)

Sensitive detection of Aβ protofibrils by proximity ligation - relevance for Alzheimer's disease
por: Kamali-Moghaddam, Masood, et al.
Publicado: (2010)

Increased Number of Plasma B Cells Producing Autoantibodies Against Aβ(42) Protofibrils in Alzheimer’s Disease
por: Söllvander, Sofia, et al.
Publicado: (2015)

Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval
por: Tolar, Martin, et al.
Publicado: (2020)

ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease
por: Honig, Lawrence S., et al.
Publicado: (2023)

Lecanemab, Aducanumab, and Gantenerumab — Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer’s Disease
por: Söderberg, Linda, et al.
Publicado: (2022)

Antibody-based PET imaging of amyloid beta in mouse models of Alzheimer's disease
por: Sehlin, Dag, et al.
Publicado: (2016)

A possible mechanism for the enhanced toxicity of beta-amyloid protofibrils in Alzheimer’s disease
por: Chen, Zu-Lin, et al.
Publicado: (2023)

Amyloid-ß-directed immunotherapy for Alzheimer's disease
por: Lannfelt, L, et al.
Publicado: (2014)

Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer’s Disease
por: Ono, Kenjiro, et al.
Publicado: (2020)

Efficient clearance of Aβ protofibrils in AβPP-transgenic mice treated with a brain-penetrating bifunctional antibody
por: Syvänen, Stina, et al.
Publicado: (2018)

The Aβ protofibril selective antibody mAb158 prevents accumulation of Aβ in astrocytes and rescues neurons from Aβ-induced cell death
por: Söllvander, Sofia, et al.
Publicado: (2018)

Amyloid Beta Annular Protofibrils in Cell Processes and Synapses Accumulate with Aging and Alzheimer-Associated Genetic Modification
por: Kokubo, Hideko, et al.
Publicado: (2009)

Antibody-Based In Vivo PET Imaging Detects Amyloid-β Reduction in Alzheimer Transgenic Mice After BACE-1 Inhibition
por: Meier, Silvio R., et al.
Publicado: (2018)

Mechanisms of U87 Astrocytoma Cell Uptake and Trafficking of Monomeric versus Protofibril Alzheimer’s Disease Amyloid-β Proteins
por: Li, Yali, et al.
Publicado: (2014)

Amyloid-β Protofibrils: Size, Morphology and Synaptotoxicity of an Engineered Mimic
por: Dubnovitsky, Anatoly, et al.
Publicado: (2013)

Increased Inflammatory Response in Cytomegalovirus Seropositive Patients with Alzheimer’s Disease
por: Westman, Gabriel, et al.
Publicado: (2014)

High tau levels in cerebrospinal fluid predict nursing home placement and rapid progression in Alzheimer’s disease
por: Degerman Gunnarsson, Malin, et al.
Publicado: (2016)

ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials
por: Wang, Jinping, et al.
Publicado: (2016)

SPECT imaging of distribution and retention of a brain-penetrating bispecific amyloid-β antibody in a mouse model of Alzheimer’s disease
por: Gustavsson, Tobias, et al.
Publicado: (2020)

Dynamics of protofibril elongation and association involved in Aβ42 peptide aggregation in Alzheimer’s disease
por: Ghosh, Preetam, et al.
Publicado: (2010)

HP9800 - HP2401 interface
por: Littlewood, R K
Publicado: (1977)

Correction: Amyloid-β Protofibrils: Size, Morphology and Synaptotoxicity of an Engineered Mimic
por: Dubnovitsky, Anatoly, et al.
Publicado: (2013)

Amyloid Oligomers and Protofibrils, but Not Filaments, Self-Replicate from Native Lysozyme
por: Mulaj, Mentor, et al.
Publicado: (2014)

Formation of amyloid loops in brain tissues is controlled by the flexibility of protofibril chains
por: Miller, Alyssa, et al.
Publicado: (2023)

Fluorine-18-Labeled Antibody Ligands for PET Imaging of Amyloid-β in Brain
por: Syvänen, Stina, et al.
Publicado: (2020)

Accumulation of amyloid-β by astrocytes result in enlarged endosomes and microvesicle-induced apoptosis of neurons
por: Söllvander, Sofia, et al.
Publicado: (2016)

Insight Into Seeded Tau Fibril Growth From Molecular Dynamics Simulation of the Alzheimer’s Disease Protofibril Core
por: Leonard, Cass, et al.
Publicado: (2021)

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
por: Swanson, Chad J., et al.
Publicado: (2021)

Atomic resolution dynamics on the surface of amyloid β protofibrils probed by solution NMR
por: Fawzi, Nicolas L., et al.
Publicado: (2011)

Considerably Unfolded Transthyretin Monomers Preceed and Exchange with Dynamically Structured Amyloid Protofibrils
por: Groenning, Minna, et al.
Publicado: (2015)

Protofibril–Fibril Interactions Inhibit Amyloid Fibril Assembly by Obstructing Secondary Nucleation
por: Hasecke, Filip, et al.
Publicado: (2020)

Amyloid-beta immunotherapy: the hope for Alzheimer disease?
por: Barrera-Ocampo, Alvaro, et al.
Publicado: (2016)

Brain pharmacokinetics of mono- and bispecific amyloid-β antibodies in wild-type and Alzheimer’s disease mice measured by high cut-off microdialysis
por: Julku, Ulrika, et al.
Publicado: (2022)

Conformation‐specific antibodies against multiple amyloid protofibril species from a single amyloid immunogen
por: Bonito‐Oliva, Alessandra, et al.
Publicado: (2019)

Correction to: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
por: Swanson, Chad J., et al.
Publicado: (2022)

Blood–brain barrier penetrating neprilysin degrades monomeric amyloid-beta in a mouse model of Alzheimer’s disease
por: Rofo, Fadi, et al.
Publicado: (2022)

The Amyloid-β Pathway in Alzheimer’s Disease
por: Hampel, Harald, et al.
Publicado: (2021)

ImmunoPET imaging of amyloid-beta in a rat model of Alzheimer’s disease with a bispecific, brain-penetrating fusion protein
por: Bonvicini, Gillian, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_on48ans82o7b9g6j0oi6fup0mr